Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of XRx-026 for the treatment of individuals who have gout and are intolerant to allopurinol

Next Previous
Search
Trial Profile

A clinical study of XRx-026 for the treatment of individuals who have gout and are intolerant to allopurinol

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XRx 026 (Primary)
  • Indications Gout
  • Focus Adverse reactions

Most Recent Events

  • 30 Apr 2025 According to a XORTX Therapeutics media release, company announced that the gout NDA may be filed in the H1 2026.
  • 30 Apr 2025 According to a XORTX Therapeutics media release, company announced that it has received responses from the US Food and Drug Administration (the FDA) and clarified key steps for a new drug application (NDA) for the Companys novel proprietary formulation of oxypurinol for the treatment of gout. The Type B meeting conducted by the FDA, included review of chemistry, manufacturing, pharmacology, toxicology and clinical evidence to support the Companys XRx-026 program for the treatment of gout.
  • 19 Mar 2025 According to a XORTX Therapeutics media release, company has prepared a Type B meeting review at the request of the FDA regarding the XRx-026 program for the treatment of gout.The purpose of this meeting will be to review the XRx-026 program and its readiness for submission of a New Drug Application to gain marketing approval for XORLO in the US using the FDA 505(b)2 development pathway. The Company believes that a Type B meeting will facilitate a broader discussion toward market approval.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top